The single intranasal administration of recombinant IL-4 (1 ng/mouse) decreased endogenous IL-4 in the HPC, increased IL-4 in the PFC, and ameliorated depression-like behaviors through the modulation of neuroinflammation and oxidative stress [63]. The gene discussed is IL4; the disease is depressive symptom measurement.